Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro

Journal of Pharmacological Sciences

Volumn 117, Issue 1, 2011, Pages 19-26

  Kinoshita, Yuichi ^a   Matsumoto, Naoki ^a   Watanabe, Minoru ^a   Takeba, Yuko ^a   Yoshida, Yutoku ^b   Ohba, Keiichiro ^b   Suzuki, Satoshi ^c   Itoh, Fumio ^a   Kumai, Toshio ^b   Kobayashi, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HAB Research Organization   (Japan)

Author keywords

Clopidogrel; Cytochrome P450 (CYP) 2C19; Drug drug interaction; Proton pump inhibitor; Ticlopidine

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; OMEPRAZOLE; RABEPRAZOLE; TICLOPIDINE;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIVER MICROSOME; PROTEIN CONTENT;

EID: 80052890010     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11048FP     Document Type: Article

References (29)

1. McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci. 2003;93:381-396. (Pubitemid 38202124)
2. Yoneda K, Iwamura R, Kishi H, Mizukami Y, Mogami K, Kobayashi S. Identification of the active metabolite of Ticlopidine from rat in vitro metabolites. Br J Pharmacol. 2004;142: 551-557. (Pubitemid 38869869)
3. Nishiya Y, Hagiwara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, et al. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xecobiotica. 2009;39:836-843.
4. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol. 2000;49:343-351.
5. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JC, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry. 2001; 40:12112-12122. (Pubitemid 32946552)
6. Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther. 2004;308: 189-197. (Pubitemid 38090717)
7. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreased the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999;47:454-457. (Pubitemid 29161281)
8. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339: 1665-1671. (Pubitemid 28550691)
9. Jacobson AK. Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Pract Res Clin Haematol. 2004;17:55-64. (Pubitemid 38780067)
10. Hallas J, Dall M, Andries A, Andersen BS, Aalykke BS, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726-730.
11. Ng FH, Lam KF, Wong SY, Chang CM, Lau YK, Yuen WC, et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008;77:173-177.
12. Gilard M, Arnaud B, Cornily JC, Gal GJ, Lacut K, Calvez GL, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 2008;51: 256-260.
13. Ho PM, Maddox TM, Wang L, Fhin SD, Jesse RL, Peterson ED. Risk of adverse outcome associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
14. Gurbel PA, Lau WC, Tantry US. Omeprazole a possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;51:261-263.
15. Li XQ, Andersson TB, Ahlström M, Weidolf M. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827. (Pubitemid 38955611)
16. Watanabe M, Tateishi T, Tanaka M, Kumai T, Kobayashi S. Role of CYP3A in bromperidol metabolism in rat in vitro and in vivo. Xenobiotica. 1999;29:839-846. (Pubitemid 29454396)
17. Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, et al. Irinotecan activate p53 with its metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci. 2007;104:232-242. (Pubitemid 47122471)
18. http://www.hab.or.jp/researcher/member/pict/info-single01.pdf (accessed December 10, 2009).
19. http://www.hab.or.jp/researcher/member/pict/info-single02.pdf (accessed December 10, 2009).
20. Yanagida Y, Watanabe M, Takeba Y, Kumai T, Matsumoto N, Hayashi M, et al. Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes. Biol Pharma Bull. 2009;32: 1422-1426.
21. Dalvie DK, O'Connell TN. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab Dispos. 2004;32:49-57. (Pubitemid 38112535)
22. Fujimaki Y, Tsumura M, Tachizawa H. [High performance liquid chromatographic methods for determination of ticlopidine in human serum]. Yakugaku Zasshi. 1986;106:1143-1145. (text in Japanese with English abstract)
23. Róna K, Ary K, Gachályi B, Klebovich I. Liquid chromatographic method for the determination of ticlopidine in human plasma. J Chromatogr B Biomed Sci Appl. 1997;693:393-398. (Pubitemid 27250301)
24. Fúrlan G, Malusá N, Strohmayer A, Klugman FB, Decorti G, Candussio L, et al. Optimised method for determination of ticlopidine in serum by high performance liquid chromatography. Pharmaco. 1996;51:747-751. (Pubitemid 27076931)
25. Nakajima T, Yonekura I, Sato A. A simple method to evaluate liver microsomal enzyme activity for phenol with a high-performance liquid chromatograph. Toxicol Lett. 1985;29:11-15. (Pubitemid 16210242)
26. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitor in healthy subjects. Pharm Res. 2001;18: 721-727. (Pubitemid 32783506)
27. Liu ZC, Uetrecht JP. Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. Drug Metab Dispos. 2000;28:726-730. (Pubitemid 30470819)
28. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitor. Biol Pharma Bull. 2003;26:386-390. (Pubitemid 39663632)
29. Furuta T, Sugimoto M, Shirai N, Ishizuki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux disease with a proton pump inhibitor. Pharmacogenomics. 2007;8:1199-1210. (Pubitemid 47578229)